Jun 13 |
Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
|
Jun 11 |
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
|
May 23 |
Zai Lab doses first subject in Phase II plaque psoriasis treatment trial
|
May 22 |
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
|
May 20 |
China’s NMPA approves Zai Lab’s XACDURO NDA for pneumonia
|
May 20 |
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
|
May 17 |
Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
|
May 16 |
Zai Lab Announces Participation in May and June Investor Conferences
|
May 14 |
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
|
May 13 |
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
|